SS-31 (elamipretide) research overview covering cardiolipin and mitochondrial hypotheses, mixed clinical trials, safety and laboratory verification.
SS-31, also called elamipretide, is a mitochondria-targeted tetrapeptide developed to interact with cardiolipin in the inner mitochondrial membrane.
It has progressed further clinically than many research peptides, but results differ by disease and endpoint. A phase 3 mitochondrial-disease trial did not meet its primary endpoints, which is important context alongside earlier signals.
Mechanism explains why a compound enters a research conversation. It does not establish that the compound is effective, appropriate or safe for a person.
Cardiolipin supports mitochondrial membrane architecture and electron-transport-chain organization. Elamipretide is studied for effects on membrane function, oxidative stress and energetic efficiency.
A coherent mitochondrial mechanism does not guarantee a clinically meaningful result. Disease biology, outcome selection and trial duration can determine whether a signal is detectable.
These are recurring questions in the published literature. They are research themes, not promised outcomes or personal recommendations.
Cellular energy restoration
Cardiovascular protection
Muscle function preservation
Neuroprotective potential
Early phase studies established human exposure and explored functional endpoints. The later MMPOWER-3 phase 3 trial did not meet its primary six-minute-walk and fatigue endpoints.
What the evidence cannot answer: Showing both results prevents selective citation. The compound remains scientifically interesting, but a failed primary endpoint is not a footnote—it changes the confidence of broad claims.
No individual COA page is currently mapped for this entry. Check the directory for a matching batch report.
Browse current lab resultsResearch-market naming does not establish identity, concentration or purity. A useful certificate of analysis identifies the batch, analytical method and measured result. Match the COA number to the vial rather than relying on a site-wide percentage or a study of a different product.
Independent verification: every certificate of analysis carries a code you can check yourself at Peptide Test Canada, an independent third-party testing lab — you don't have to take our word for it.
An individual report is not currently mapped for this entry. The absence is shown plainly so a directory link cannot be mistaken for product-specific verification.
Mitochondrial symptoms overlap with cardiac, endocrine, hematologic, sleep and medication-related conditions; diagnosis cannot be made from fatigue alone.
Product status: Quantum’s SS-31 material is research-use-only and is not represented as an authorized prescription product.
The tracker ties the schedule to exercise tolerance, fatigue pattern, symptoms, medications and clinician-directed markers.
Cadence, timing and cycle are owner-draft previews. Dose, dilution, titration, inventory, check-ins and change history remain inside the tracker after purchase.
Concise answers that keep mechanism, evidence, product quality and regulatory status separate.
SS-31, also called elamipretide, is a mitochondria-targeted tetrapeptide developed to interact with cardiolipin in the inner mitochondrial membrane.
Cardiolipin supports mitochondrial membrane architecture and electron-transport-chain organization. Elamipretide is studied for effects on membrane function, oxidative stress and energetic efficiency.
Early phase studies established human exposure and explored functional endpoints. The later MMPOWER-3 phase 3 trial did not meet its primary six-minute-walk and fatigue endpoints. Clinical benefit remains indication-specific and unproven for general energy, exercise or longevity claims.
Quantum’s SS-31 material is research-use-only and is not represented as an authorized prescription product.
This educational page does not provide a protocol. Published exposure, when available, is specific to the studied or authorized product and cannot be transferred to Quantum’s research-use-only material. Use the tracker only as an organizational record, not a substitute for qualified medical care.
Check the current lab-results directory for a report that matches the vial’s identity and batch number. No individual COA page is currently mapped for this entry, so do not rely on a general purity claim.